This series is for clinicians, nurses, APPs to have a forum to discuss the management of complex lymphoma cases. During this we discuss appropriate management options, clinical trial availability, and recently published data that would guide our decision making. We review pathology, radiological images, and clinical course for each patient presented.
Key Words: Lymphoma, Treatment, Pathology
- Physician
- Nurse Practitioner
- Physician Assistant
- Nurse
- Pharmacist
- Psychologist
- Social Worker
Participants who engage in this educational intervention will be able to:
- Manage of complex lymphoma cases
- Utilize diagnostic and pathological tools utilized to characterize a lymphoma
- Improve patient outcomes through group discussion
Planning Committee:
Nirav Shah, MD (Activity Director)
Associate Professor Department of Medicine
Division of Hematology & Oncology
The Medical College of Wisconsin
Sumana Devata, MD
Associate Professor Department of Medicine
Division of Hematology & Oncology
The Medical College of Wisconsin
Timothy Fenske, MD
Professor Department of Medicine
Division of Hematology & Oncology
The Medical College of Wisconsin
Mehdi Hamadani, MD
Professor Department of Medicine
Division of Hematology & Oncology
The Medical College of Wisconsin
Walter Longo, MD
Professor Department of Medicine
Division of Hematology & Oncology
The Medical College of Wisconsin
In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
- Sumana Devata, MD
- Walter Longo, MD
The following persons in control of content disclosed the following financial relationships which were reviewed via the MCW conflict of interest mitigation process and addressed.
Name | Company | Role |
---|---|---|
Nirav Shah, MD | Loxo-Lilly | Consultant, Researcher |
Miltenyi Biotec | Consultant, Researcher | |
Epizyme | Advisory Board | |
Janssen | Advisory Board | |
Kite Pharma | Advisory Board | |
Incyte | Advisory Board | |
Seattle Genetics | Advisory Board | |
Novartis | Advisory Board | |
BMS-Juno | Advisory Board | |
TG Therapeutics | Advisory Board | |
Umoja | Advisory Board | |
Tundra Therapeutics | Advisory Board/Founder | |
Timothy Fenske, MD | Kite Pharmaceuticals | Consultant/Speaker |
TG Therapeutics | Consultant/Speaker | |
AbbVie | Consultant | |
AstraZeneca | Consultant | |
Bristol-Myers Squibb | Consultant | |
Biogen | Consultant | |
Servier | Consultant | |
MorphoSys | Consultant | |
Sanofi | Consultant | |
Mehdi Hamadani, MD | Janssen | Consultant |
Incyte | Consultant | |
ADC Therapeutics | Consultant | |
Omeros | Consultant | |
MorphoSys | Consultant | |
Kite Pharmaceuticals | Consultant | |
Takeda | Research/Funding | |
Spectrum Pharmaceuticals | Research/Funding | |
Astellas Pharma | Research/Funding | |
Sanofi | Speaker | |
Genzyme | Speaker | |
AstraZeneca | Speaker | |
BeiGene | Speaker |
Contact
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
- 1.00 MOC Part IIMOC Part II credit.